At Origami Therapeutics, Dr. Hoffman is creating a new approach to discovering curative medicines for neurodegenerative diseases, leveraging her experience from 20 years of CNS drug discovery and from discovering transformational therapies for Cystic Fibrosis (CF). Prior to Origami, she was a Research & Development Executive at Vertex Pharmaceuticals, Amgen and Eli Lilly & Co. She made major contributions to >30 programs that advanced to clinical trials and to four marketed drugs for CF (Kalydeco, Orkambi, Symdeco, Trikafta) that created a paradigm shift in CF treatment by targeting the underlying cause of the disease to modulate protein folding. She directly contributed to label expansions for Kalydeco, enlarging its market and increasing sales by >$1 billion. In addition, she led the research generating a novel non-opioid pain therapeutic, now in Phase 3 development. Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University. She was awarded the Prize of the Anna Monika Foundation for depression research. Dr. Hoffman serves on the Board of Directors for Biofrontera Inc. (NASDAQ: BFRI), the SAB for the Tau Consortium and the National Board of Trustees for the Huntington’s Disease Society of America (HDSA).